Misra Durga P, Rathore Upendra, Patro Pallavi, Agarwal Vikas, Sharma Aman
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, 226014, India.
School of Telemedicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, 226014, India.
Rheumatol Ther. 2021 Sep;8(3):1073-1093. doi: 10.1007/s40744-021-00355-3. Epub 2021 Aug 16.
We conducted a systematic review of patient-reported outcome measures (PROMs) regarding quality of life, disability, mood abnormalities (anxiety, depression), fatigue, illness perceptions and fibromyalgia in Takayasu arteritis (TAK). Wherever available, comparisons with healthy controls, disease controls or longitudinal changes in PROMs were noted.
MEDLINE, EMBASE, Scopus, Web of Science and Pubmed Central databases, major recent international rheumatology conference abstracts, clinical trial databases and the Cochrane library were searched for relevant articles. Wherever possible, outcome measures across studies were pooled using the restricted maximum likelihood model. Inter-group differences were pooled and compared using standardized mean differences (SMD) with 95% confidence intervals (95% CI). Heterogeneity was assessed using the I statistic. Quality of randomized controlled trials was assessed using the Cochrane risk of bias tool. For cross-sectional and cohort studies, the Joana Briggs Institute checklist and Newcastle-Ottawa scale were used, respectively. GRADE methodology was used to determine the certainty of evidence for outcomes.
Twenty-one studies (all but one observational) involving 1311 patients with TAK and 308 healthy controls were identified. Ten studies (559 TAK patients, 182 healthy controls were synthesized in a meta-analysis. Patients with TAK had worse quality of life (pooled SMD - 6.66, 95% CI - 10.08 to - 3.23 for individual domains; - 0.64, 95% CI - 1.19 to - 0.09 for pooled physical and mental component scores of 36-item Short Form Survey), depression (SMD 0.26, 95% 0.05-0.47) and anxiety (SMD 0.34, 95% CI - 0.06 to 0.75) scores and higher disability (SMD 0.64, 95% CI 0.43-0.84) than healthy controls. Patients with active TAK had worse quality of life, depression and work impairment when compared with those with inactive disease. Included studies were of moderate to high quality. Certainty of evidence for individual outcomes was low to very low.
Literature on PROMs in TAK, albeit sparse, appears to indicate worse scores in patients with TAK compared to healthy individuals. These results, however, require cautious interpretation. Development of a TAK-specific PROM is an important focus of the research agenda.
我们对关于高安动脉炎(TAK)患者的生活质量、残疾、情绪异常(焦虑、抑郁)、疲劳、疾病认知和纤维肌痛的患者报告结局指标(PROMs)进行了系统评价。只要有数据,我们就记录了与健康对照、疾病对照的比较或PROMs的纵向变化。
检索MEDLINE、EMBASE、Scopus、Web of Science和Pubmed Central数据库、近期主要国际风湿病学会议摘要、临床试验数据库和Cochrane图书馆以查找相关文章。只要有可能,就使用限制最大似然模型汇总各研究的结局指标。使用标准化均数差(SMD)和95%置信区间(95%CI)汇总并比较组间差异。使用I统计量评估异质性。使用Cochrane偏倚风险工具评估随机对照试验的质量。对于横断面研究和队列研究,分别使用乔安娜·布里格斯研究所检查表和纽卡斯尔-渥太华量表。采用GRADE方法确定结局证据的确定性。
共纳入21项研究(除1项为观察性研究外均为观察性研究),涉及1311例TAK患者和308例健康对照。10项研究(559例TAK患者,182例健康对照)被纳入荟萃分析。与健康对照相比,TAK患者的生活质量较差(单个领域的汇总SMD为-6.66,95%CI为-10.08至-3.23;36项简短调查问卷的汇总生理和心理成分得分的SMD为-0.64,95%CI为-1.19至-0.09)、抑郁(SMD为0.26,95%CI为0.05 - 0.47)和焦虑(SMD为0.34,95%CI为-0.06至0.75)得分更高,残疾程度更高(SMD为0.64,95%CI为0.43 - 0.84)。与疾病不活动的患者相比,活动期TAK患者的生活质量、抑郁和工作障碍更严重。纳入的研究质量为中等至高。单个结局的证据确定性为低至极低。
关于TAK中PROMs的文献虽然稀少,但似乎表明TAK患者的得分比健康个体更差。然而,这些结果需要谨慎解读。开发特定于TAK的PROM是研究议程的一个重要重点。